Form 4: Iovance Biotherapeutics CFO Reports Stock Transactions
SEC Form 4 Filing
Jean-Marc Bellemin, CFO of Iovance Biotherapeutics, filed a Form 4 detailing the vesting of restricted stock units and subsequent tax withholding.
Summary
- On September 3, 2024, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, had 23,438 restricted stock units (RSUs) vest.
- The company withheld 11,891 shares to satisfy tax obligations at a price of $10.85 per share.
- Following these transactions, Bellemin directly owns 29,348 shares of common stock and 23,437 restricted stock units.
- The remaining RSUs will vest on March 1, 2025.
Sentiment
Score: 5
Explanation: This is a routine filing related to executive compensation, and it doesn't indicate any significant positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.
Stakeholder Impact
- The vesting of RSUs and subsequent tax withholding may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| March 1, 2024 | Date of initial grant of RSUs. |
| September 3, 2024 | Date of RSU vesting and tax withholding. |
| March 1, 2025 | Date of remaining RSU vesting. |
| September 5, 2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.